Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners Part D Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    2026 Medicare Part D Prior Authorization Requirements — Part D formulary coverage criteria

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists prior authorization requirements, criteria, and coverage details for multiple prescription drugs on the HealthPartners 2026 Medicare Part D formulary; applies to Part D benefits and prescribers/providers submitting PA requests.

    Policy Summary
    PayerHealthPartners
    PolicyMedicare Part D prior authorization and coverage criteria for selected drugs (Part D formulary)
    Policy CodePolicy N/A
    Change TypeTechnical/periodic review (no material changes)
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with required diagnostic documentation and evidence of prior therapy trials or contraindications as specified for the requested drug.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    26132formulary FID
    04/01/2026effective date
    12 monthscommon duration
    Yesprerequisite therapy
    multiplePA drugs shown

    Coverage Criteria (Per-Drug Entries)

    Dalfampridine — Initial therapy criteria

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for dalfampridine (e.g., improvement of walking in multiple sclerosis)
    • Patient is currently able to walk 25 feet
    • Physician attestation that the patient has difficulty walking

    Deferasirox — Initial therapy criteria

    Covered when ALL of the following are met:

    ANY of the following

    Policy Summary
    PayerHealthPartners
    PolicyMedicare Part D prior authorization and coverage criteria for selected drugs (Part D formulary)
    Policy CodePolicy N/A
    Change TypeTechnical/periodic review (no material changes)
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with required diagnostic documentation and evidence of prior therapy trials or contraindications as specified for the requested drug.
    SourceLink
    On This Page
    Coverage Criteria (Per-Drug Entries)Initial Therapy Criteria (Grouped Examples)Continuation and Renewal CriteriaProvider Actions, Prior Authorization & DocumentationCoding and Affected ProductsStep Therapy RequirementsQuantity Limits and DurationSite of Care & Part B vs Part D DeterminationsBackground and RationaleDefinitions and Diagnostic Thresholds
    Diagnosis of chronic iron overload due to a non‑transfusion dependent thalassemia syndrome with BOTH: (a) liver iron concentration (LIC) ≥ 5 mg Fe/g dry weight, and (b) serum ferritin > 300 mcg/L
  1. OR diagnosis of chronic iron overload due to blood transfusions with BOTH: (a) ongoing regular blood transfusions for conditions such as thalassemia syndromes, MDS, chronic anemia, or sickle cell disease, and (b) serum ferritin > 1,000 mcg/L prior to starting therapy
  2. Enbrel — Coverage criteria

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for Enbrel (etanercept)
    • For rheumatoid arthritis: moderate–severe disease with medical contraindication or inadequate response to methotrexate, hydroxychloroquine, leflunomide, or sulfasalazine for at least 3 months
    • For juvenile idiopathic arthritis: medical contraindication or inadequate response to one NSAID or methotrexate for 1 month (as applicable)
    • For plaque psoriasis: ≥3% BSA or involvement of palms/soles/face/scalp/genital regions or pustular psoriasis with inadequate response to topical corticosteroids for 4 weeks or systemic therapies as appropriate
    • Patient does not have an FDA‑labeled limitation of use or contraindication to therapy

    Glutamine — Coverage criteria

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for oral glutamine
    • Documentation supporting the intended use (e.g., management of chemotherapy‑induced mucositis as per labeled/compendia guidance)

    Epidiolex — Coverage criteria

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for cannabidiol (Epidiolex)
    • Documentation of the specific seizure disorder (e.g., Lennox‑Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex) with prior trials of appropriate standard therapies or contraindication/intolerance to them

    Teriparatide — Initial and renewal criteria

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of osteoporosis in a patient at high risk for fracture (or other FDA‑approved indication for teriparatide)
    • Documentation of prior fracture or failure/intolerance to conventional osteoporosis therapies (e.g., bisphosphonates) unless contraindicated

    Immunoglobulin products — Initial coverage criteria

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for the immunoglobulin product (e.g., primary immunodeficiency, CIDP maintenance, MMN, ITP as specified per product)
    • Confirmatory diagnostic testing or documentation supporting the indication (e.g., immunoglobulin deficiency testing for primary immunodeficiency; electrophysiologic and clinical confirmation for CIDP/MMN)
    • Patient does not have an FDA‑labeled limitation of use or contraindication to therapy

    GATTEX — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of short bowel syndrome with intestinal failure requiring parenteral support, with documentation of malabsorption and need for intestinal rehabilitation (GATTEX [teduglutide] indication)
    • Documentation that patient is being managed in an appropriate multidisciplinary program and goals for reducing parenteral support are established

    GLP‑1 receptor agonists — Coverage criteria

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for a GLP‑1 receptor agonist (e.g., type 2 diabetes; other FDA‑approved uses)
    • Documentation confirming diagnosis of type 2 diabetes (ICD‑10 code, medical records, chart notes, A1C or lab results) when used for diabetes

    Hadlima — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis consistent with an FDA‑approved indication for Hadlima (adalimumab) or biosimilar
    • Documentation of prior therapy or contraindication per indication and any relevant step‑therapy (as required)

    Ibrutinib (Imbruvica) — Coverage criteria

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for ibrutinib (Imbruvica/Imbruvica tablets) such as CLL/SLL, mantle cell lymphoma, WM, cGVHD after failure of at least one systemic therapy, consistent with product labeling
    • For tablet formulations (140 mg, 280 mg) provide rationale if unable to use preferred capsules/tablets or listed preferred strengths/forms

    Ibrance — Coverage criteria

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for palbociclib (Ibrance) or other indicated agent
    • Documentation supporting indication (e.g., HR+/HER2‑ advanced/metastatic breast cancer) and use in accordance with labeled/compendia guidance

    Diabetes supplies — Part D coverage condition

    Part D coverage condition: covered when ALL of the following are met:

    ALL of the following

    • Supplies are for use by a patient enrolled in the Part D plan and consistent with a covered outpatient medication under Part D (e.g., insulin administration supplies when insulin is covered under Part D)
    • Documentation supports that the supplies are necessary for administration or monitoring of a Part D‑covered drug (e.g., syringes, sharps disposal, glucose test strips when Part D covers the associated medication under plan rules)

    Kerendia — Initial and renewal

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for Kerendia (finerenone), such as chronic kidney disease associated with type 2 diabetes per labeling
    • Documentation of baseline eGFR and albuminuria consistent with labeled indication and that patient is on optimized renin‑angiotensin system therapy as appropriate

    Kesimpta — Initial

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis consistent with an FDA‑approved indication for Kesimpta (ofatumumab) and documentation of prior therapies or contraindications per disease‑specific requirements

    Kineret — Initial and renewal

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for anakinra (Kineret) such as rheumatoid arthritis or other labeled inflammatory disorders
    • Documentation of prior therapies and medical necessity where applicable

    Kisqali / Femara — Initial and renewal

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication requiring combination endocrine therapy such as HR+ advanced/metastatic breast cancer where ribociclib (Kisqali) and letrozole (Femara) use is indicated
    • Documentation supporting indication and prior/concurrent therapies per guideline or compendia recommendations

    Lidocaine patch & Linezolid — Initial and renewal

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis and intended use consistent with labeled indications for lidocaine patch or linezolid
    • Documentation of prior therapies, medical necessity, and appropriate monitoring (e.g., for linezolid: duration limits, drug interaction review) as clinically indicated

    LIVTENCITY — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for Livtencity (maribavir) such as treatment of post‑transplant CMV infection that is refractory to or resistant to available antivirals
    • Documentation of CMV viremia and prior antiviral therapy/resistance testing as appropriate per labeling

    MAVYRET — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of chronic hepatitis C infection for which MAVYRET (glecaprevir/pibrentasvir) is indicated per labeling
    • Documentation of genotype and prior treatment history per labeling/compendia and absence of contraindications

    LYNPARZA — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for olaparib (LYNPARZA) such as BRCA‑mutated ovarian or breast cancer per labeling
    • Documentation of genetic testing results when indicated and prior therapy history consistent with labeled use

    Nitazoxanide — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of nitazoxanide‑responsive condition per FDA or compendia (e.g., cryptosporidiosis in certain populations) and documentation supporting need

    Nitisinone — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for nitisinone and supporting confirmatory testing (e.g., hereditary tyrosinemia type 1) per labeling

    Otezla — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of psoriasis or psoriatic arthritis where apremilast (Otezla) is indicated, or other FDA‑approved indication
    • Documentation of prior topical and/or systemic therapy trials or contraindications per indication

    Pirfenidone — Initial therapy for IPF

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of idiopathic pulmonary fibrosis (IPF) where pirfenidone is indicated
    • Documentation of pulmonary function testing and prior therapies as appropriate

    Repatha — Hyperlipidemia (HeFH/ASCVD/HoFH)

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of hyperlipidemia consistent with FDA‑labeled indications for Repatha (evolocumab) such as HeFH, clinical ASCVD requiring additional LDL lowering, or HoFH
    • Documentation of baseline lipid values and prior trial of maximally tolerated statin therapy (and ezetimibe when appropriate) unless contraindicated

    Rezdiffra — Initial and renewal therapy

    Initial therapy criteria (covered when ALL are met):

    ALL of the following

    • Diagnosis of nonalcoholic steatohepatitis (NASH)/MASH with moderate–advanced fibrosis when Rezdiffra (investigational/approved as per labeling) is indicated per labeling or compendia
    • Documentation of fibrosis stage and other baseline evaluations supporting therapy selection

    Signifor (Cushing's disease) — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of Cushing disease where pasireotide (Signifor) is indicated per labeling
    • Documentation of biochemical and clinical findings supporting need for therapy and prior surgical/other therapy status per guidelines

    Sildenafil (PAH) — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of pulmonary arterial hypertension (WHO Group 1) where sildenafil is indicated per labeling, with right heart catheterization confirmation when required
    • Documentation that patient does not have contraindications and is managed by a cardiologist or pulmonologist

    Sirturo (MDR‑TB) — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of multidrug‑resistant tuberculosis (MDR‑TB) for which bedaquiline (Sirturo) is indicated per guidelines
    • Documentation of prior TB treatment history, drug susceptibility testing, and specialist (infectious disease/pulmonology) management

    Rubraca — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for rucaparib (Rubraca) and supporting genetic testing where indicated
    • Documentation of prior therapies per labeling/compendia

    NORDITROPIN — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis and documentation supporting growth hormone use per FDA‑approved indications for Norditropin (e.g., growth hormone deficiency)

    NORDITROPIN — Renewal

    Covered when ALL of the following are met:

    ALL of the following

    • For renewal of NORDITROPIN: documentation of continued clinical benefit, growth velocity or other appropriate markers, and specialist follow‑up

    SOMAVERT — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of acromegaly where pegvisomant (Somavert) is indicated per labeling
    • Documentation of prior therapies, IGF‑1 levels, and specialist management

    STELARA — Initial therapy and step therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for ustekinumab (Stelara) and documentation of prior therapies or contraindications per step‑therapy requirements
    • For initial therapy, failure or intolerance to preferred agents as specified in disease‑specific criteria (step therapy) must be documented

    TRIKAFTA — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of cystic fibrosis with at least one F508del mutation or other mutation responsive to elexacaftor/tezacaftor/ivacaftor (Trikafta) per labeling
    • Documentation of genetic testing confirming mutation(s) and prior therapy history as appropriate

    TRIKAFTA — Renewal

    Renewal criteria (covered when ALL are met):

    ALL of the following

    • For Trikafta renewal: documentation that patient has been seen by prescriber within the past 12 months and that medication has demonstrated efficacy (e.g., stabilized or improved pulmonary function)

    Tadalafil (PAH) — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of PAH where tadalafil is indicated and right heart catheterization confirmation provided when required by indication
    • Documentation of prior/contraindicated therapies and specialist management

    VENCLEXTA — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for venetoclax (VENCLEXTA) with appropriate disease and molecular testing as required (e.g., CLL with 17p deletion, AML with IDH mutation where indicated)
    • Documentation of prior therapies and treatment plan including dose ramp‑up and tumor lysis prophylaxis as clinically required

    VERQUVO — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of heart failure with reduced ejection fraction where Verquvo (vericiguat) is indicated per labeling
    • Documentation of guideline‑directed medical therapy trials or intolerance to components and specialist/cardiology involvement

    Voriconazole — Indications

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an FDA‑approved indication for voriconazole and documentation of invasive fungal infection requiring therapy
    • Prior therapy trials or contraindications documented per indication (e.g., intolerance to other azoles) when required

    Vosevi — Initial therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis and documentation supporting use of Vosevi (sofosbuvir/velpatasvir/voxilaprevir) per labeled hepatitis C treatment indications
    • Documentation of prior DAA therapy and resistance profile when applicable

    Initial coverage criteria — rifaximin / DIFICID

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of recurrent C. difficile infection where rifaximin or fidaxomicin (DIFICID) criteria apply
    • Documentation of prior therapies and clinical course per product‑specific initial coverage criteria

    Initial coverage criteria — XOLAIR (omalizumab)

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of eosinophilic or allergic disease for which omalizumab (Xolair) is indicated and documentation of prior therapies or biomarkers as required (e.g., IgE levels, eosinophil counts) per labeling

    Initial coverage criteria — YESINTEK

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis and documentation supporting use of YESINTEK per labeled indications

    Initial coverage criteria — Zejula

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis and documentation supporting use of Zejula (niraparib) per labeled indications, including genetic testing when indicated

    Initial coverage criteria — Zurzuvae

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis and documentation supporting use of Zurzuvae per labeled indications

    Initial Therapy Criteria (Grouped Examples)

    Imbruvica — Initial and Renewal

    Covered when ALL of the following are met:

    Imbruvica initial: Diagnosis of an FDA‑approved indication not otherwise excluded from Part D.

    For some entries prescriber must be or consult a hematologist; renewal requires seen within last 12 months and positive response

    Imbruvica dosing and renewal: Limited to dose within FDA‑labeled dosing guidelines; renewal requires patient seen within last 12 months and positive response.

    Coverage duration varies by entry (6 or 12 months)

    Inqovi — Initial and Renewal

    Covered when ALL of the following are met:

    Inqovi initial criteria: Diagnosis of an FDA‑approved indication AND genetic testing completed if required with results supporting use; AND for MDS inadequate response or contraindication to azacitidine (Part B before Part D may apply for MA‑PD beneficiaries).

    Renewal requires positive response; coverage duration six months; limited to FDA dosing

    Neurogenic Orthostatic Hypotension (NOH) initial criteria

    Covered when ALL of the following are met

    NOH initial criteria summary: (1) Diagnosis of symptomatic neurogenic orthostatic hypotension due to specified causes; (2) orthostatic BP drop ≥20 mmHg systolic OR ≥10 mmHg diastolic within 3 minutes of standing; (3) trial/failure of at least two first‑line therapies; (4) prescriber cardiology/neurology consult recommended.see thresholds

    Coverage one month then three months if renewal criteria met

    Inbrija — Initial and Renewal

    Covered when ALL of the following are met:

    Inbrija initial criteria: Parkinson's disease with OFF episodes AND patient is taking carbidopa/levodopa AND trial and failure of at least one adjunct agent for ≥4 weeks in combination with carbidopa/levodopa AND provider attestation of inhaler education and documentation of pulmonary status (no underlying lung disease or FEV <50% with attestation benefits outweigh risks).

    Prescribed by or in consultation with a neurologist; renewal requires positive response; coverage 12 months

    Tolvaptan — Initial

    Covered when ALL of the following are met:

    Tolvaptan initial criteria: Diagnosis of ADPKD with prescriber attestation of rapidly‑progressing disease (examples: declining renal function, increasing total kidney volume) AND nephrology consultation where indicated.

    Exclusions: concurrent use with Samsca (tolvaptan tablets) and patients with stage 5 CKD; prescribed by or in consultation with nephrology

    INCRELEX - Initial therapy

    Covered when ALL of the following are met:

    INCRELEX initial criteria: Diagnosis of an FDA‑approved indication AND for severe primary IGF‑1 deficiency or GH gene deletion with neutralizing antibodies to GH: height SDS ≤ -3.0 AND basal IGF‑1 SDS ≤ -3.0.height SDS <= -3.0; basal IGF-1 SDS <= -3.0

    Prescribed by or in consultation with an endocrinologist; coverage 12 months

    NEXLETOL - Initial therapy

    Covered when ALL of the following are met:

    NEXLETOL initial criteria: Diagnosis of an FDA‑approved indication AND for HeFH or ASCVD with LDL above goal despite therapy: trial of a high‑intensity statin plus ezetimibe concomitantly for at least 8 weeks with LDL remaining >70 mg/dL OR documented statin intolerance (defined per policy).8 weeks trial; LDL >70 mg/dL

    Prescriber preferably cardiology/endocrinology; coverage 12 months; limited to FDA dosing

    Nucala (mepolizumab) severe asthma initial criteria

    Covered when ALL of the following are met

    Nucala severe asthma initial: Diagnosis of severe asthma AND pre‑treatment serum eosinophil count ≥150 cells/mcL within prior 12 months AND inadequate asthma control despite medium/high‑dose inhaled corticosteroid plus at least one other maintenance medication AND inadequate control defined by exacerbation or hospitalization criteria.>=150 cells/mcL

    Renewal requires evidence of response

    OFEV (nintedanib) initial criteria

    Covered when ALL of the following are met (per indication):

    OFEV IPF criteria: For IPF: exclusion of other ILD causes and HRCT UIP pattern OR HRCT/histopathology combinations indicative of IPF; baseline FVC ≥50% and %DLCO ≥30%; AND inadequate response or contraindication to pirfenidone.FVC >=50%; %DLCO >=30%

    Prescribed by or in consultation with pulmonology/rheumatology; coverage 12 months; renewal requires visit within 14 months and positive response

    OFEV progressive ILD criteria: For chronic fibrosing ILD with progressive phenotype: >10% fibrotic features on HRCT and clinical progression (FVC decline ≥10% OR FVC decline ≥5% plus worsening symptoms/imaging) with baseline FVC ≥45% and %DLCO ≥30%.FVC >=45%; %DLCO >=30%

    Renewal: positive response

    Modafinil and related agents - Initial therapy

    Modafinil and related agents covered with criteria for multiple indications:

    Modafinil initial criteria (selected): Diagnosis of an FDA‑approved indication AND for OSA: either ≥15 obstructive events/hour on sleep study OR ≥5 events/hour plus at least one qualifying symptom (unless sleep study not feasible); for narcolepsy: confirmatory polysomnography and MSLT unless not feasible; for shift‑work disorder: sleep study demonstrating disturbed sleep‑wake pattern with exclusion of other causes; adjunctive uses require prior therapy trials as specified.OSA thresholds per sleep study

    Initial coverage 6 months then 12 months if renewal criteria met; may not be used concurrently with armodafinil

    Continuation and Renewal Criteria

    Abiraterone continuation

    Renewal/continuation rules noted where specified.

    Abiraterone continuation: Renewal requires positive response to therapy and documentation per policy.

    Coverage duration: six months per authorization

    Prolastin-C continuation

    Prolastin‑C continuation requirements

    Prolastin-C continuation: Patient must have been seen within the past 12 months and show positive response to therapy for renewal.

    Coverage duration 12 months

    Continuation/Renewal

    Renewal/continuation requirements (examples):

    General renewal: Renewal generally requires positive response to therapy and documentation of recent follow‑up visit (examples: BENLYSTA within 14 months; ATTRUBY within 12 months; many products require evidence of efficacy).

    Coverage durations commonly 12 months on renewal

    Renewal requirements

    Renewal conditions across listed biologics:

    Biologic renewal: Renewal typically requires evidence that treatment goals have been met or positive clinical response as judged by the provider; typical renewal interval is 12 months for many biologics such as CIMZIA and COSENTYX.

    CRESEMBA continuation

    CRESEMBA renewal:

    CRESEMBA renewal: Positive response to therapy to extend coverage from initial 3 months to 6 months.

    General renewal requirements

    Renewal/continuation commonly requires:

    Renewal common requirements: Positive response to therapy documented and periodic clinician follow‑up (examples: OFEV requires seen within last 14 months); coverage durations commonly 12 months on renewal.

    Venclexta continuation

    Venclexta renewal

    Venclexta renewal: Renewal requires documented positive response to therapy.

    Coverage duration six months

    Renewal rules

    Renewal/continuation requirements where specified

    Imbruvica renewal: Patient has been seen within the last 12 months and demonstrates positive response to therapy.

    Coverage duration varies by entry

    Kalydeco renewal: Patient has been seen within the last 12 months and demonstrates positive response to therapy.

    Coverage duration 12 months

    CONTINUATION CRITERIA

    RETACRIT renewal rules

    Retacrit renewal: Indication‑specific renewal criteria (examples include hemoglobin thresholds for CKD, pediatric and cancer contexts) and evidence of continued benefit.

    See product page for details

    Verzenio continuation

    Verzenio renewal

    Verzenio renewal: Renewal requires positive response to therapy per prescriber documentation.

    Coverage duration six months

    Voriconazole continuation

    Voriconazole renewal

    Voriconazole renewal: Renewal requires positive response to therapy; coverage duration varies by indication (1 month for esophageal candidiasis; 6 months for other indications).

    Prescriber specialist consultation recommended

    Xdemvy continuation

    Xdemvy renewal

    Xdemvy renewal: Renewal requires positive response to therapy as documented by prescriber.

    Coverage duration six weeks

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Abiraterone — prior authorization & documentation

    Prior authorization required. Initial requests must document diagnosis of an FDA‑approved indication not excluded from Part D, completion of genetic testing if required with results supporting abiraterone use (when applicable), and absence of any FDA‑labeled limitation of use or contraindication unless supported by NCCN. If requesting the 500 mg tablet provide rationale why the 250 mg tablet cannot be used. Limit dosing to within FDA‑labeled guidelines; coverage duration: six months. Renewal requires documented positive response to therapy.

    Step Therapy

    Actemra — step therapy and PA

    Prior authorization required. Initial approval requires diagnosis of one of the listed indications and inadequate response or medical contraindication to preferred drugs as specified (e.g., RA or polyarticular JIA: inadequate response to at least two preferred agents). Prescriber should be or consult a rheumatologist or pulmonologist. Do not use concurrently with other biologic therapies. Coverage duration: 12 months.

    Prior Authorization

    Adempas — hemodynamics & PA

    Prior authorization required for PAH/CTEPH. Submit diagnostic confirmation (right heart catheterization showing mean PAP ≥20 mmHg, PCWP ≤15 mmHg, PVR >2 Wood units for Group 1 PAH) and prescriber specialty (cardiology or pulmonology). Do not use concurrently with nitrates, nitric oxide donors, PDE inhibitors, or non‑specific PDE inhibitors. Coverage duration: 12 months.

    Documentation Required

    Armodafinil — sleep study & concurrency

    Prior authorization required. For OSA, provide sleep study showing ≥15 obstructive events/hour or ≥5 events/hour plus qualifying symptoms (or prescriber statement if study not feasible). Do not use concurrently with modafinil or other target agents. Initial coverage 6 months; renewal to 12 months if response.

    Prior Authorization

    ATTRUBY — diagnostic confirmation & exclusions

    Prior authorization required for ATTR‑CM. Provide cardiac biopsy or noninvasive diagnostic evidence (serum/urine immunofixation and free light chain ratio within 0.26–1.65 and myocardial 99mTc‑PYP uptake heart‑to‑contralateral ratio >1.5 or visual grade ≥2), HF history and NYHA class I–III documentation, and prescriber cardiology involvement. Do not use concurrently with ONPATTRO or TEGSEDI. Coverage: 12 months; renewal requires seen within 12 months and demonstrated efficacy.

    Documentation Required

    BENLYSTA — serology, prior therapy & renewal

    Prior authorization required for BENLYSTA SC. Provide serologic evidence (anti‑dsDNA >30 IU/mL, low complement C3/C4, or anti‑Smith), documentation of continuation of standard‑of‑care therapy, and inadequate response or contraindication to two listed alternatives. Do not use concurrently with another biologic agent. Renewal requires positive response and visit within 14 months; coverage duration: 12 months.

    Documentation Required

    Bosentan — hemodynamics & liver labs

    Prior authorization required for bosentan. Provide right heart catheterization hemodynamics confirming Group 1 PAH (mean PAP ≥20 mmHg, PCWP ≤15 mmHg, PVR >2 Wood units) and liver tests showing ALT/AST ≤3×ULN and bilirubin not ≥2×ULN prior to start. Do not use concurrently with cyclosporine A or glyburide. Coverage duration: 12 months.

    Step Therapy

    CIMZIA — step therapy, prescriber restriction

    Prior authorization required. Initial CIMZIA requests must document the indication and failure or contraindication to at least two preferred drugs for that indication, and be prescribed by or in consultation with an appropriate specialist (rheumatologist, dermatologist, gastroenterologist). Concurrent use with other biologic therapies is prohibited; dose limited to FDA labeling; coverage: 12 months.

    Prior Authorization

    COSENTYX — PA, prescriber restriction

    Prior authorization required. COSENTYX requests must document the FDA‑approved indication, prescriber specialty (dermatologist or rheumatologist), and prior therapy failures per indication. Do not use concurrently with other biologic therapies. Limit to FDA‑labeled dosing; coverage duration: 12 months.

    Prior Authorization

    CRESEMBA — prior therapy & coverage duration

    Prior authorization required for oral isavuconazole (CRESEMBA). Document the FDA‑approved diagnosis and inadequate response or contraindication to voriconazole or posaconazole as indicated. Initial coverage is 3 months and may be extended to 6 months with positive response; prescriber should be or consult ID/transplant/hematology/oncology specialist.

    Prior Authorization

    Prior authorization — general requirement

    Prior authorization is required for many products; initial and renewal approvals require indication‑specific clinical criteria (diagnosis, severity, required labs, prior therapy failures or contraindications) and dosing limited to FDA‑labeled guidelines.

    Prior Authorization

    GAMMAGARD LIQUID — PA & site‑of‑care note

    PA applies to GAMMAGARD LIQUID. Submit documentation of the FDA‑approved indication (e.g., primary immunodeficiency, CIDP maintenance) and meet product‑specific exclusions; coverage duration: 12 months. Note: Part B vs Part D determination may be required based on setting.

    Prior Authorization

    GAMUNEX‑C — PA & documentation

    PA required for GAMUNEX‑C. Provide diagnosis consistent with FDA‑approved indication (primary immunodeficiency, CIDP maintenance, ITP after intolerance to conventional therapy) and required clinical details; coverage duration: 12 months. Part B vs Part D setting may affect coverage.

    Documentation Required

    GATTEX — SBS documentation & dose limit

    Prior authorization required for GATTEX. Document short bowel syndrome with ≥1 year parenteral nutrition dependence, inability or plan to taper PN, required colonoscopy/FOBT per age, and limit dose to 0.05 mg/kg/day (FDA dose). Coverage: 12 months.

    Documentation Required

    GLP‑1 agonists — diabetes documentation

    PA required for GLP‑1 receptor agonists. Provide documentation confirming diagnosis of type 2 diabetes (ICD‑10, chart notes, A1C or labs). Coverage duration: 12 months.

    Step Therapy

    Hadlima — step therapy & concurrency

    Hadlima requires prior authorization. Initial requests must meet disease‑specific criteria and document inadequate response or contraindication to required conventional therapies (step therapy). Do not use concurrently with other biologics; limit dose to FDA‑labeled dosing.

    Prior Authorization

    Imbruvica — formulation preference & PA

    Imbruvica requires prior authorization. Provide diagnosis consistent with FDA‑approved hematologic or cGVHD indications; for certain tablet strengths (140 mg, 280 mg) document intolerance or contraindication to preferred strengths/forms. Coverage duration: six months; dose limited to FDA‑labeled dosing.

    Documentation Required

    Tolvaptan — ADPKD attestation & exclusions

    Prior authorization required for tolvaptan (ADPKD). Submit prescriber attestation of rapidly‑progressing disease, nephrology consultation, and note exclusions (concurrent Samsca use, stage 5 CKD).

    Documentation Required

    Kalydeco — genetic requirement & prescriber

    Kalydeco prior authorization: document diagnosis of cystic fibrosis, presence of at least one responsive CFTR mutation per in vitro data, and that patient is not homozygous for F508del. Prescriber should be or consult CF specialist/pulmonologist. Renewal requires visit within 12 months and positive response; coverage 12 months.

    Documentation Required

    Kerendia — labs & prior ACE/ARB trial

    Kerendia prior authorization: document UACR ≥30 mg/g, eGFR ≥25 mL/min/1.73 m2, serum potassium ≤5.0 mEq/L prior to start, and trial of (or intolerance to) an ACE inhibitor or ARB. Renewal requires positive response and continued ACE intolerance or continuation; coverage 12 months.

    Prior Authorization

    LIVTENCITY — CMV prior therapy & concurrency

    Prior authorization required for LIVTENCITY. Document active CMV infection in HSCT or SOT patients and inadequate response or contraindication to ganciclovir, valganciclovir, foscarnet, or cidofovir; prescriber must be or consult transplant/ID specialist. Do not use concurrently with those antivirals. Coverage duration: eight weeks.

    Documentation Required

    MAVYRET — HCV labs & drug interactions

    MAVYRET prior authorization: ensure adherence to AASLD/IDSA guidance, HCV RNA within past 6 months, and that patient is not concurrently taking listed interacting drugs (e.g., carbamazepine, rifampin, certain statins, cyclosporine >100 mg/day). Prescriber should be or consult GI/hepatology/ID/transplant specialist; coverage 8–16 weeks per guideline.

    Prior Authorization

    LYNPARZA — indication‑specific testing & PA

    LYNPARZA requires prior authorization. Initial requests must document the FDA‑approved indication and indication‑specific requirements (e.g., BRCA/HRD status or prior therapy responses). Limit dosing to FDA labeling; coverage duration: six months.

    Prior Authorization

    Nucala — eosinophil threshold & prior therapy

    For severe eosinophilic asthma (Nucala), prior authorization requires pre‑treatment eosinophil ≥150 cells/µL within prior 12 months, inadequate control despite medium/high‑dose inhaled steroid plus another maintenance med, and defined exacerbation history; renewal requires evidence of response.

    Documentation Required

    Rezdiffra — diagnostic confirmation & renewal

    Rezdiffra prior authorization: confirm diagnosis of MASH/NASH with moderate‑advanced fibrosis (stage F2 or F3) by liver biopsy or elastography/CT/MRI, document prescriber counseling on diet and exercise, and prescribe by or consult endocrinology/gastro/hepatology. Renewal requires ≥1 year therapy without fibrosis worsening or progression to F4.

    Documentation Required

    Prior authorization — provider documentation required

    General prior authorization requirement: providers must submit indication‑specific clinical documentation (diagnosis, labs/imaging, prior therapy trials or contraindications, specialist consults where specified) and requests are generally limited to doses within FDA‑labeled guidelines; many approvals default to 12 months.

    Prior Authorization

    Venclexta — PA & contraindication check

    Venclexta prior authorization: document FDA‑approved diagnosis (e.g., CLL/SLL or AML in combination regimens), confirm no FDA‑labeled contraindication, and limit dosing to FDA labeling. Renewal requires documented positive response; initial coverage up to six months.

    Prior Authorization

    Verquvo — HF criteria & specialist consult

    Verquvo prior authorization: document EF <45%, NYHA II–IV, and either ≥1 HF hospitalization in past 6 months or outpatient IV diuretics in past 3 months, plus inadequate response or contraindication to at least two guideline therapies (ACE/ARB/ARNI, beta‑blocker, aldosterone antagonist, or SGLT2). Prescriber should be or consult a cardiologist. Coverage duration: 12 months.

    Documentation Required

    Xalkori — genetic testing & PA

    Xalkori prior authorization: provide FDA‑approved indication documentation and completion of required genetic testing with supportive results when applicable (e.g., ROS1 or ALK). Patient must not have unsupported FDA‑labeled limitations; coverage duration: six months; dose limited to FDA labeling.

    Step Therapy

    Xeljanz — step therapy & concurrency exclusion

    Xeljanz prior authorization: document diagnosis per indication and inadequate response or contraindication to at least two preferred drugs specific to each indication. Do not use concurrently with other biologic therapies. Prescriber should be or consult rheumatology/dermatology/gastroenterology; coverage duration: 12 months.

    Prior Authorization

    Xifaxan/rifaximin — indication‑specific PA & dosing limits

    Rifaximin (Xifaxan) PA required per indication. For hepatic encephalopathy document lactulose dose‑limiting side effects and prescriber follow‑up; for IBS‑D document inadequate response/contraindication to first‑line therapies and limit dosing to 550 mg TID for 14 days (retreatment limited to patients with prior positive response, max two 14‑day courses); for travelers' diarrhea document trial/failure or resistance to listed antibiotics (duration 3 days).

    Documentation Required

    Xolair — IgE testing & concurrency exclusion

    Xolair prior authorization: initial requests must document the FDA‑approved indication and, for severe asthma, positive allergy testing and baseline IgE ≥30 IU/mL plus inadequate control on inhaled corticosteroid and another maintenance med. Xolair may not be used concurrently with another monoclonal antibody therapy.

    Prior Authorization

    Zejula & Zurzuvae — indication‑specific PA

    Zejula and Zurzuvae require prior authorization. Zejula: document FDA‑approved indication and population‑specific eligibility (maintenance after response to platinum chemo); coverage six months. Zurzuvae (postpartum depression): document onset timing (third trimester or within 4 weeks postpartum) and prescriber attestation about driving/operating machinery counseling; coverage 14 days.

    Note

    Index — consult individual drug pages

    This index lists drugs and page references only; providers must consult each drug's policy page for specific prior authorization, step therapy, documentation, and denial rules.

    Denial Risk

    Denial risk — FDA‑labeled limitations/contraindications

    Requests may be denied if the patient has an FDA‑labeled limitation of use or a contraindication to the requested therapy; verify product‑specific labeled limitations/contraindications before submission.

    Denial Risk

    Denial risk — concurrent biologic/monoclonal antibody use

    Do not approve concurrent use of listed biologic/monoclonal antibody therapies — e.g., Actemra, BENLYSTA, CIMZIA, COSENTYX, DUPIXENT, Nucala, Xolair, YESINTEK and others — unless policy explicitly allows it; concurrent biologic use is an exclusion and may trigger denial.

    Denial Risk

    Denial risk — missing/unsupported genetic testing

    Denial risk: requests for targeted oncology agents that require genetic testing (e.g., Xalkori) will be denied if required genetic testing is not completed or results do not support use.

    Documentation Required

    Genetic testing — documentation required

    If genetic testing is required for the requested oncology agent, include completed test results demonstrating the appropriate mutation or biomarker prior to PA submission; lack of supporting results may preclude approval (examples: Xalkori, LYNPARZA where BRCA/HRD status is required).

    Coding and Affected Products

    Part D / Covered NDCs and drug productsmixedCovered
    GAMUNEX-CGAMUNEX-C immune globulin
    GATTEX 30-VIALGATTEX (alpha-1 proteinase inhibitor) 30-vial
    GATTEX ONE-VIALGATTEX one-vial presentation
    HADLIMAHADLIMA biosimilar (adalimumab)
    HADLIMA PUSHTOUCHHADLIMA PushTouch device
    HADLIMA(CF)HADLIMA cystic fibrosis presentation
    HADLIMA(CF) PUSHTOUCHHADLIMA(CF) with PushTouch
    HIZENTRAHIZENTRA subcutaneous immune globulin
    IBRANCEIBRANCE (palbociclib)
    INBRIJA INHALATION CAPSULEINBRIJA levodopa inhalation capsules
    1–10 of 42
    1/5

    Step Therapy Requirements

    Step requirementDetails
    Step through preferred agents before Actemra
    Actemra initial criteria require inadequate response or medical contraindication to at least two preferred drugs for the indicated condition (examples: rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis — preferred drugs listed include Hadlima, Simlandi, Rinvoq; giant cell arteritis requires inadequate response to at least one preferred drug). Prescriber restriction: prescribed by or in consultation with a rheumatologist or pulmonologist. Coverage duration: 12 months.
    Step requirementDetails
    Step through preferred antidepressants before listed agents
    For new starts of certain antidepressant products, approval requires diagnosis of an FDA‑approved indication and prior inadequate response or medical contraindication to two preferred alternative antidepressants (examples: trials of two listed alternatives such as SSRI/SNRI/class agents). Prescriber: typically neurology/psychiatry as indicated. Coverage duration: 12 months.
    RequirementExamples / Notes
    Required prior trials of specified alternatives before approval
    Several products require documented inadequate response or contraindication to specified alternative therapies prior to approval. Examples: antipsychotics require failure/contraindication to two alternatives (lurasidone, risperidone, ziprasidone, olanzapine, quetiapine, aripiprazole); CIMZIA and similar biologics require failure or contraindication to at least two preferred drugs specific to each indication (preferred lists enumerated per disease). Documentation of prior trials must be submitted with initial PA.
    Documentation requirementWhat to include
    Documentation of prior therapy trials or contraindications required as part of initial PA.
    Initial prior authorization requests must include evidence of prior inadequate response or medical contraindication to the specified preferred or first‑line therapies (e.g., CIMZIA, COSENTYX, DUPIXENT). For biologics and specialty agents include therapy names, durations, and reason for discontinuation (failure or intolerance). Prescriber specialty consultation/notes should be included when required.
    Prior therapy requirementExamples / Thresholds
    Failure or contraindication to specified prior therapies required before coverage.
    Examples: Enbrel — inadequate response to at least one preferred adalimumab agent (Hadlima, Simlandi) or specified conventional therapies; Glutamine (sickle cell) — ≥2 painful crises in prior 12 months despite hydroxyurea unless contraindicated; Epidiolex — inadequate response to two antiseizure medications; Teriparatide — inadequate response to another osteoporosis therapy (e.g., bisphosphonates). Documentation of prior trials and durations required.
    RequirementDetails
    Trial of specified conventional therapies prior to biologic (Hadlima)
    Hadlima initial approval requires prior trial and inadequate response or contraindication to specified conventional therapies depending on indication (examples: methotrexate, hydroxychloroquine, leflunomide, or sulfasalazine for rheumatoid arthritis; NSAID or methotrexate for juvenile idiopathic arthritis; topical/systemic therapy durations noted). Documentation of trials and durations must be provided with PA.
    RequirementPolicy detail
    Use preferred Imbruvica strengths/forms unless intolerance or contraindication documented
    Imbruvica authorization specifies preferred strengths/formulations (capsules 70 mg/140 mg, 420 mg tablet, 70 mg/mL suspension). Requests for certain tablet strengths (140 mg and 280 mg) require documentation of intolerance or medical contraindication to preferred strengths/forms. Renewal requires recent visit and positive response; coverage duration typically six months.
    RequirementExamples
    Proof of prior therapy failure or contraindication required before approval.
    Examples: Inqovi (MDS) — inadequate response or contraindication to azacitidine (Part B before Part D for some beneficiaries); Jaypirca entries — prior therapies including BTK/BCL‑2 inhibitors as specified; Kisqali — prior inadequate response or contraindication to a preferred drug such as Verzenio or Ibrance. Providers must submit documentation of prior trials/failures or contraindications with the PA request.
    RequirementDetails
    Trial of high-intensity statin plus ezetimibe for minimum 8 weeks or documented statin intolerance
    For PCSK9/adjunct lipid therapies (example NEXLETOL, Repatha), prior trial of a high‑intensity statin plus ezetimibe concomitantly for at least 8 weeks with LDL remaining above goal (e.g., >70 mg/dL) is required unless documented statin intolerance (e.g., rhabdomyolysis to one statin or unresolved muscle symptoms to both atorvastatin and rosuvastatin). Documentation of statin/ezetimibe trial duration and LDL values must be provided.
    RequirementDetails
    Required prior antibiotic trial or documented resistance
    For travelers' diarrhea due to noninvasive E. coli, approval of rifaximin (or related agents) requires trial and failure or contraindication to one of ciprofloxacin, levofloxacin, ofloxacin, or azithromycin, or documented resistance to all listed antibiotics. Documentation of antibiotic trials or resistance must be submitted with PA. Coverage duration for travelers' diarrhea is typically 3 days; IBS‑D and hepatic encephalopathy have different duration rules.

    Quantity Limits and Duration

    inv-469: abiraterone dose restriction
    Quantity restrictionAbiraterone dosing must be limited to doses within FDA-labeled dosing guidelines.
    Provider actionIf 500 mg tablet requested, provide rationale why 250 mg tablet cannot be used.
    Coverage duration noteInitial authorization: six months when criteria met.
    inv-470: Adempas dose restriction
    Quantity restrictionAdempas dosing limited to doses within FDA-labeled dosing guidelines.
    Clinical documentationPrior authorization requires right heart catheterization confirmation for Group 1 PAH (mPAP ≥20 mmHg, PCWP ≤ 15 mmHg, PVR >2 WU).
    Coverage durationAuthorization duration: 12 months when criteria met.
    inv-471: Multiple listed products dose limits
    General ruleMultiple listed products: dose is limited to within FDA-labeled dosing guidelines.
    Applies toBiologics, oncology agents, specialty drugs referenced throughout the policy (product-specific exceptions noted in entries).
    Authorization implicationRequests exceeding FDA dosing limits require rationale and may be denied absent supporting evidence.
    inv-472: Sirturo coverage duration 24 weeks
    Coverage durationSirturo (bedaquiline) coverage duration specified as 24 weeks.
    Use contextAuthorized for MDR-TB as part of combination regimen when resistance or adverse reactions to standard agents exist.
    Prescriber requirementPrescribed by or in consultation with an infectious disease specialist.
    inv-473: Signifor duration (3 months then 12 months if renewal criteria met)
    Initial durationSignifor initial authorization: 3 months.
    RenewalThen 12 months if renewal criteria are met (for Cushing's disease: 12 months).
    ContraindicationPatient must not have severe hepatic impairment for Signifor use.
    inv-475: XIFAXAN dosing
    Dose and regimenXIFAXAN (rifaximin) dosing for IBS-D: 550 mg three times daily for 14 days.
    Other indications/durationsHepatic encephalopathy: coverage 12 months (with lactulose intolerance); travelers' diarrhea: 3 days dosing per label.
    Retreatment limitsIBS-D retreatment limited to patients with prior positive response, up to two 14-day treatments.
    inv-476: Rifaximin (for IBS-D) dosing limit
    IBS-D dosing limitRifaximin for IBS-D: 550 mg three times daily for 14 days (retreatment limited to patients with prior positive response; max two 14-day courses).
    Hepatic encephalopathyRifaximin coverage for hepatic encephalopathy requires lactulose dose-limiting side effects; coverage 12 months.
    Travelers' diarrheaFor travelers' diarrhea due to noninvasive E. coli: regimen limited to 3 days with prior antibiotic trial/failure or documented resistance as specified.
    inv-477: Zurzuvae 14-day treatment course
    Treatment courseZurzuvae (brexanolone) limited to a 14-day treatment course for postpartum depression per policy.
    Initiation requirementsOnset of symptoms must be in the third trimester or within four weeks of delivery; prescriber attestation about driving/operating machinery counseling is required.
    Dose limitsDose limited to FDA-labeled dosing guidelines.

    Site of Care & Part B vs Part D Determinations

    Note

    Site‑of‑care — Part B vs Part D may affect coverage

    Confirm whether administration or dispensing setting affects benefit (Part B vs Part D). For some drugs (e.g., certain immunoglobulins, amphotericin products, Gammagard Liquid, Vivtencity, Xatmep) providers must supply the setting/use details to determine correct coverage.

    Note

    Site‑of‑care — provide setting when requested

    Some drugs may be covered under Part B or Part D depending on setting; provide information about the administration/dispensing setting when requested to determine the correct benefit (examples include immunoglobulins and certain injectables/infusion drugs).

    Note

    Immunoglobulins — setting may determine Part B vs Part D

    Certain immunoglobulin products may be covered under Part B or Part D depending on circumstance and setting; submit setting details (infusion center vs home) and indication to support correct benefit determination.

    Note

    Mixed Part B/Part D coverage — provide setting details

    Some drugs have mixed site‑of‑care determinations; for products such as paricalcitol, PULMOZYME, or Retacrit, submit details of the dispensing/administration setting to establish benefit responsibility.

    Note

    Mixed coverage — document use & setting for benefit determination

    Coverage may be under Part B or Part D depending on circumstances (e.g., Xatmep); documentation of the clinical use and setting may be requested to determine the correct benefit.

    Documentation Required

    Vowst — bowel prep & single‑course administration

    Vowst administration requires completion of bowel preparation (magnesium citrate) the day before and at least 8 hours prior to initiation; confirm patient completed antibiotic therapy 2–4 days prior. Coverage limited to a single 10‑day treatment course.

    Background and Rationale

    This policy provides clinical context and documentation expectations tied to specific drug indications. It is intended to guide the information required for prior authorization rather than offer full clinical guidance. Key elements include hemodynamic criteria for pulmonary arterial hypertension (right heart catheterization thresholds), pretreatment laboratory thresholds (e.g., alpha‑1 antitrypsin levels), and specialty prescriber recommendations. Providers should supply indication‑specific diagnostics, evidence of prior therapies or contraindications where required, and attestations (for example, inhaler education or diet/exercise counseling) to support PA requests.

    Definitions and Diagnostic Thresholds

    inv-397: Right heart catheterization confirmation for Group 1 PAH
    RequirementRight heart catheterization confirmation for Group 1 PAH defined by: mean PAP ≥20 mmHg, PCWP ≤ 15 mmHg, and PVR >2 Wood units.
    Use in policiesNeeded for PAH agents (e.g., Adempas, Opsumit, Winrevair) as part of prior authorization documentation.
    PrescriberPrescribed by or in consultation with a cardiologist or pulmonologist per product-specific requirements.
    inv-398: Pretreatment serum alpha-1 antitrypsin (AAT) level thresholds
    ThresholdsPretreatment serum alpha-1 antitrypsin (AAT) level thresholds: <11 micromoles/L; or <80 mg/dL by radial immunodiffusion; or <57 mg/dL by nephelometry.
    ContextRequired for Prolastin-C initial authorization in AAT deficiency with clinically evident emphysema.
    RenewalRenewal requires patient seen within past 12 months and positive response to therapy.
    inv-399: Obstructive Sleep Apnea (OSA) diagnostic thresholds
    OSA diagnostic thresholdsObstructive sleep apnea (OSA) diagnosis: >=15 obstructive respiratory events/hour on sleep study, OR >=5 events/hour plus at least one symptom (daytime sleepiness, unintentional sleep episodes, unrefreshing sleep, fatigue, insomnia, waking with breath-holding/gasping/choking, loud snoring, or breathing interruptions).
    DocumentationSleep study results are required unless prescriber documents study is not feasible for armodafinil PA requests.
    ApplicationUsed to determine eligibility for armodafinil for OSA per policy.
    inv-400: Narcolepsy confirmation
    ConfirmationNarcolepsy confirmation requires polysomnography and multiple sleep latency test (MSLT) unless prescriber documents that sleep study is not feasible.
    ContextRequired for armodafinil and modafinil prior authorization when narcolepsy is the indication.
    RenewalRenewal requires positive response to therapy per product criteria.
    inv-401: Positive response to therapy
    DefinitionPositive response to therapy: clinical improvement as judged by provider (e.g., symptom control, reduction in exacerbations, objective measures as appropriate).
    Use for renewalMany products require documented positive response for renewal (e.g., BENLYSTA, Inqovi, multiple biologics).
    DocumentationProvider attestation and recent visit documentation usually required (timing varies by product).
    inv-402: Inadequate asthma control
    Clinical definitionInadequate asthma control is defined as at least one exacerbation requiring oral systemic corticosteroids >=3 days within the last 12 months, OR at least one serious exacerbation requiring hospitalization or ER visit in the last 12 months.
    ApplicationUsed for eligibility for biologics like DUPIXENT and XOLAIR requiring inadequate control despite maintenance therapy.
    DocumentationProvider must document exacerbation history or hospital/ER events when requesting biologic therapy for asthma.
    inv-403: Atopic dermatitis severity
    Severity thresholdAtopic dermatitis considered moderate to severe when BSA >= 10% or involvement of face, neck, hands, feet, genitals, or intertriginous areas with intractable pruritus or cracking/oozing/bleeding.
    UseApplied to DUPIXENT initial authorization for atopic dermatitis.
    DocumentationProvider must document BSA or involvement of critical areas and prior topical therapy failures as specified.
    inv-404: Eosinophilic asthma pre-treatment lab
    Pre-treatment labEosinophilic asthma pre-treatment serum eosinophil count >=150 cells/mcL within the previous 12 months.
    PurposeRequired for initial authorization of biologics for eosinophilic asthma (e.g., DUPIXENT, Nucala).
    RenewalRenewal requires evidence of positive clinical response per product-specific criteria.
    inv-405: Short Bowel Syndrome (SBS)
    DefinitionShort bowel syndrome (SBS): clinical condition of insufficient intestinal length/function requiring dependence on parenteral nutrition; GATTEX initial PA requires ≥1 year PN dependence and inability or planned inability to taper PN.
    DocumentationColonoscopy or fecal occult blood testing required per age group prior to GATTEX initiation.
    PrescriberPrescribed by or in consultation with a gastroenterologist.
    inv-406: Hereditary Angioedema (HAE) diagnostic testing
    Confirmatory testsHAE diagnostic testing includes C1-INH antigenic level, C1-INH functional level, and C4 level; genetic mutations (e.g., factor XII, PLG) may establish diagnosis.
    ApplicationRequired for prophylaxis (HAEGARDA) and acute treatment (icatibant) authorizations.
    PrescriberPrescribed by or in consultation with hematology/allergy/immunology specialists as indicated.
    inv-407: FVC
    FVC baseline thresholdsForced vital capacity (FVC) baseline thresholds for antifibrotic therapy: >=50% for IPF; >=45% for certain progressive ILD.
    UseRequired for OFEV and pirfenidone initial authorizations and monitoring.
    RenewalRenewal commonly requires evidence of positive response and recent prescriber follow-up per product policy.
    inv-408: Right heart catheterization parameters
    Right heart cath parametersFor PAH confirmation: mean PAP ≥20 mmHg; PCWP ≤ 15 mmHg; PVR >2 Wood units (policy references these as required hemodynamics).
    ApplicationUsed for eligibility documentation for multiple PAH therapies (Adempas, Opsumit, Winrevair, etc.).
    PrescriberPrescribed by or in consultation with cardiology or pulmonology specialists per product-specific requirements.
    inv-409: MASH/NASH with fibrosis staging
    DefinitionMASH/NASH with fibrosis staging: diagnosis confirmed by liver biopsy or elastography/CT/MRI showing stage F2 or F3 fibrosis for Rezdiffra initial approval.
    Treatment requirementMust be used in combination with diet and exercise counseling (prescriber confirmation required).
    RenewalRenewal requires >=1 year of therapy without fibrosis worsening or progression to F4 (cirrhosis).
    inv-410: WHO Group 1 PAH diagnostic criteria
    WHO Group 1 PAH diagnostic criteriaRight heart catheterization with mean pulmonary arterial pressure ≥20 mmHg, PCWP ≤ 15 mmHg, and PVR ≥3 Wood units (policy notes PVR thresholds for some agents).
    UseRequired for certain PAH agent approvals (e.g., sildenafil requires PVR ≥3 WU per policy).
    DocumentationRight heart catheterization report must be submitted with PA requests when required by product-specific criteria.
    inv-412: Wilson's disease diagnostic criteria
    Diagnostic criteriaWilson's disease diagnosis confirmed by two of: ATP7B mutation, Kayser-Fleischer rings, neurological symptoms, hepatic abnormality, low ceruloplasmin (<20 mg/dL), urinary copper >40 mcg/24h, or hepatic parenchymal copper >40 mcg/g dry weight.
    UseRequired for initiation of trientine when penicillamine intolerance present per policy.
    RenewalRenewal requires prescriber follow-up within past 12 months and positive response.